Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma AidsDHA:PHARMAID -2.55%73 EV-to-FCF is 323.03 as of Jul. 17, 2026, which is 455% above its 10-year median of 58.23. GuruFocus rates DHA:PHARMAID with a GF Score™ of 73/100 and a GF Value™ of BDT758.56 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 414 Medical Devices & Instruments companies, Pharma Aids ranks worse than 94.2% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pharma Aids's Enterprise Value is BDT1,989.6 Mil.
Pharma Aids's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was BDT6.2 Mil. Therefore, Pharma Aids's EV-to-FCF for today is 323.03.
The historical rank and industry rank for Pharma Aids's EV-to-FCF or its related term are showing as below:
DHA:PHARMAID'
s EV-to-FCF Range Over the Past 10 Years
Min: -1503.19 Med: 58.23 Max: 845.45
Current: 291.42
During the past 13 years, the highest EV-to-FCF of Pharma Aids was 845.45. The lowest was -1503.19. And the median was 58.23.
DHA:PHARMAID's EV-to-FCF is ranked worse than 94.2% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.635
vs DHA:PHARMAID: 291.42
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pharma Aids's PE Ratio (TTM) for today is calculated as:
Pharma Aids's share price for today is BDT644.70.
Pharma Aids's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-931.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pharma Aids EV-to-FCF Related Terms
Pharma Aids EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Pharma Aids's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:PHARMAID vs ISRG, BDX, MDLN: EV-to-FCF Comparison
For the Medical Instruments & Supplies subindustry, Pharma Aids's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Aids EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pharma Aids's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Pharma Aids's EV-to-FCF falls into.
Pharma Aids's current Enterprise Value is BDT1,989.6 Mil.
Pharma Aids's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT6.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Aids (DHA:PHARMAID) has a EV-to-FCF of 323.03 as of Jul. 17, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pharma Aids and its competitors. This is 455% above median its historical median of 58.23. According to the industry distribution chart, Pharma Aids ranks #390 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 94.2%.
Is Pharma Aids' EV-to-FCF too high?
Pharma Aids' current EV-to-FCF of 323.03 is 455% above median its 10-year median of 58.23. The Medical Devices & Instruments industry median EV-to-FCF is 23.64. Pharma Aids' value of 323.03 is 1266.7% above this industry median. Based on the distribution chart, Pharma Aids ranks #390 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Pharma Aids ranks #390 out of 414 companies for EV-to-FCF. This places Pharma Aids in the lower half of its industry. The industry median EV-to-FCF is 23.64. Pharma Aids' value of 323.03 is 1266.7% above this benchmark. While the company's 10-year median is 58.23 vs. the industry median of 23.64, Pharma Aids has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.64, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Aids's current EV-to-FCF of 323.03 is 1266.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pharma Aids and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Aids's current EV-to-FCF is 323.03, which is 455% above median its own 10-year median of 58.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT758.56, compared to a current price of BDT644.70 — trading 15% below its estimated fair value. The current EV-to-FCF is 323.03, which is 455% above median its 10-year median of 58.23 and 1266.7% above the Medical Devices & Instruments industry median of 23.64. Pharma Aids' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current EV-to-FCF is 323.03 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued.
The current stock price of BDT644.70 is trading 15% below its estimated GF Value™ of BDT758.56.
GuruFocus considers Pharma Aids to be Modestly Undervalued.
Key valuation signals for DHA:PHARMAID:
EV-to-FCF: 323.03 (455% above median its 10-year median of 58.23)
GF Value™: BDT758.56 vs. price of BDT644.70 (15% below fair value)
Industry Position: 1266.7% above the Medical Devices & Instruments median (#390 of 414)
No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score
Get the complete analysis for DHA:PHARMAID
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:PHARMAID has been successfully added to your 
